AIMT

Aimmune Therapeutics, Inc.
AIMT

Overview Fund Activity
Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

74 hedge funds and large institutions have $319M invested in Aimmune Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
74
Holders Change
+5
Holders Change %
+7.25%
% of All Funds
1.98%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.08%
New
13
Increased
40
Reduced
13
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
PAMU
1
Pictet Asset Management (UK)
United Kingdom
$12.8M
2
VC
2
Vivo Capital
California
$8.26M
3
BBA
3
Baker Bros. Advisors
New York
$7.29M
4
BFA
4
BlackRock Fund Advisors
California
$6.74M
5
EAM
5
Eagle Asset Management
Florida
$21.5M

Top Sellers

1
SAM
1
Sectoral Asset Management
Quebec, Canada
$0
2
EC
2
EcoR1 Capital
California
$0
3
RIM
3
RS Investment Management
California
$5.82M
4
Fidelity Investments
4
Fidelity Investments
Massachusetts
$52.8M
5
FCMI
5
Foresite Capital Management III
California
$2.54M
Name Holding Trade Value Shares
Change 		Shares
Change %
Federated Hermes
76
Federated Hermes
Pennsylvania
– -$678K -50,000 Closed
TC
77
TFS Capital
Pennsylvania
– -$316K -23,302 Closed
DTL
78
Dynamic Technology Lab
Singapore
– -$229K -16,873 Closed
Goldman Sachs
79
Goldman Sachs
New York
– -$212K -15,639 Closed
LCM
80
Laurion Capital Management
New York
– -$149K -11,000 Closed
SO
81
STRS Ohio
Ohio
– -$48K -3,600 Closed
1 2 3
4